Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hiltonol + Anti-PD-1/PD-L1 in Advanced Solid Cancers
NCT03721679Phase 2Terminated
- Sponsor
- Oncovir, Inc.
- Start
- Sep 2018
- Primary completion
- Jan 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of poly iclc in solid tumor cancer, sponsored by Oncovir, Inc.. Started Sep 2018; status: terminated.
02
Drugs
poly iclc
03
Conditions
solid tumor cancer
Beyond the preview
Go deeper on NCT03721679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721679.